alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 76–100 of 105 studies in Frontiers in Neurology (page 4 of 5) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of these 105 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Combined with multimodal medical imaging and artificial intelligence for early diagnosis of Parkinson's disease

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Frontiers in Neurology 2025-10-01

Epidemiological data show that both PD incidence rate and prevalence rate show a significant age-dependent growth trend [3]. 5 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer's Disease and Cerebral Amyloid Angiopathy

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Frontiers in neurology 2015-09-25

Amyloid-related imaging abnormalities (ARIA) represent the major severe side effect of amyloid-beta (Aβ) immunotherapy for Alzheimer's disease (AD). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Formation and propagation of tau oligomeric seeds

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Frontiers in neurology 2013-07-17

Tau misfolding and aggregation leads to the formation of neurofibrillary tangles (NFTs), which have long been considered one of the main pathological hallmarks for numerous neurodegenerative diseases known as tauopathies, including Alzheimer's Disease (AD) and Parkinson's Disease (PD). 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Iatrogenic cerebral proteinopathies—The dawn of transmissible neurodegeneration? The example of cerebral amyloid angiopathy

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Frontiers in Neurology 2025-11-05

Several reports confirmed possible inadvertent iatrogenic intracranial transmission of Aβ pathology via medical and surgical procedures (1,2).A common molecular mechanism, described in prion diseases, is proposed to trigger the replication and spread of different misfolded proteins in the central nervous system (CNS), causing different neurodegenerative diseases associated with disease-specific proteins such as α-synuclein in Parkinson's disease, and amyloid-beta (Aβ) in Alzheimer's disease, and cerebral amyloid angiopathy (CAA) (3). 5 key findings →

Participants: 125 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Emerging biomarkers and frontier therapies: unveiling the role of endothelial dysfunction in cerebral small vessel disease

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Frontiers in Neurology 2025-07-11

Cerebral small vessel disease (cSVD), a major contributor to stroke, cognitive decline, and vascular dementia, accounts for around 25% of ischemic strokes and significantly impacts age-related neurological disability. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Brain Amyloid Burden and Resting-State Functional Connectivity in Late Middle-Aged Hispanics

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Frontiers in neurology 2020-10-06

Non-linear relations of brain amyloid beta (Aβ) with task- based functional connectivity (tbFC) measured with functional magnetic resonance imaging (fMRI) have been reported in late middle age. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

Research progress of multimodal biomarkers in the early diagnosis of mild cognitive impairment in Parkinson’s disease

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Frontiers in Neurology 2025-08-29

Parkinson's disease (PD), as a common neurodegenerative disorder, its associated mild cognitive impairment (PD-mild cognitive impairment, PD-MCI) is a key prodromal stage in the progression to PD-dementia (PDD). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Clinicopathological features of primary tauopathies: a brain bank series

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Frontiers in Neurology 2026-03-30

Fifteen cases were identified, spanning argyrophilic grain disease, primary age-related tauopathy, corticobasal degeneration, genetic frontotemporal dementia, and progressive supranuclear palsy. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Incidence trends and age-period-cohort analysis of Alzheimer’s disease and other dementias in the world and China from 1990 to 2021: analyses based on the Global Burden of Disease Study 2021

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Frontiers in Neurology 2025-07-04

From 1990 to 2021, the incidence, prevalence, and DALYs of ADOD have significantly risen both globally and in China, with the growth rates in China notably surpassing the global average. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Nef is a key player in neuroinflammation and myelin impairment associated with neuroHIV

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Frontiers in Neurology 2025-03-12

In particular, the severity of HIV-associated neurocognitive disorders (HAND) has been greatly reduced, significantly decreasing the prevalence of HIV-associated dementia [1]. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

From clinical judgment to biology: a clinician's opinion on the use of blood-based biomarkers in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Frontiers in Neurology 2026-04-08

This position is justified by the fact that not all individuals with positive biomarkers will progress to symptomatic disease, as well as by the considerable variability in biomarker results depending on the type of marker and the laboratory performing the analysis (3).Both frameworks agree that biomarkers enhance diagnostic certainty but differ in the degree of reliance placed upon them. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Assessment of heart rate deceleration capacity, heart rate deceleration runs, heart rate acceleration capacity, and lipoprotein-related phospholipase A2 as predictors in individuals with dementia

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Frontiers in Neurology 2025-01-09

Our studies showed that DC and DRs in VD and AD groups were significantly lower than those in controls, while AC values were significantly higher. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed